At 135-Times Sales, Cannabis Valuations Make No Sense Whatsoever

Let’s put into perspective what Aurora Cannabis Inc.’s (TSX:ACB) trailing twelve month price to sales ratio actually means.

The claim that businesses introducing innovative and disruptive technologies or those in industries that are still in their infancy with impressive long-term potential for explosive growth should have valuation multiples ascribed to their stock prices is not up for debate. From Amazon.com, Inc. (NASDAQ:AMZN) to Shopify Inc. (TSX:SHOP)(NYSE:SHOP), investors are used to paying extremely high valuation multiples over extended periods in disruptive high-margin companies.

The Canadian cannabis sector has begun to exhibit emerging-tech valuation multiples – valuations that, as I have previously stated, are “exhibiting concrete signs of overvaluation, creeping into bubble territory.

Case in point: let’s take a look at the trailing twelve-month (TTM) price-to-sales ratios for four of Canada’s largest (publicly traded) cannabis producers:

Company Market Capitalization Price/Sales Ratio
Aurora Cannabis Inc. $3.15 billion 135.6
Aphria Inc. $2.04 billion 92.1
Canopy Growth Corp. $3.71 billion 76.0
Medreleaf Corp. $1.46 billion 35.5

As the chart above shows, Aurora Cannabis Inc. (TSX:ACB) emerges as the clear winner, with a price to TTM sales of 136 taking the cake, while Medreleaf Corp. (TSX:LEAF) comes in at a “measly” 36 times sales, making this $1.5 billion company the “best value” of the bunch using this metric. Aphria Inc. (TSX:APH) and Canopy Growth Corp. (TSX:WEED) round out the group with price/sales multiples of 92 and 76, respectively.

A healthy price-to-sales ratio in most industries tends to be below 1.5. A number of high-profile analysts and academics have pointed to the dangers of investing in companies with price-to sales-ratios above 1.5, given the reality of what a price-to-sales ratio actually means.

In layman’s terms, a price-to-sales ratio of 136 means is that Aurora would need to pay its investors 136 years’ worth of the company’s trailing twelve-month revenue in order for investors to get their money back. This implies a zero cost of goods, 100% profit margin, and stable revenue over time.

As we know, a great deal of growth is forecasted into Aurora’s valuation, and the company is expected to grow at a triple-digit pace for some time to come. That said, the math uses crazy assumptions that bear no resemblance to reality.

I’ve run a financial model on Aurora and extended its 168.6% year-over-year growth rate out five years (the typical length most analysts forecast out to). Assuming investors would pay $7.00 per share in Q4 2022, the valuation still doesn’t make sense.

Do the math, it’s an interesting exercise.

Looking at a price/sales ratio that is currently nearly 100x – considered the top end of the spectrum for investment-grade companies – Aurora’s current valuation doesn’t provide much in the way of room for error.

Valuations for projected market size make no sense, either

Looking at the four aforementioned companies, we can see that the total combined market capitalizations of these firms at the time of writing sits at $10.36 billion, with a total (disputed) estimated market size upon legalization of between $4.2 billion and $6.2 billion in 2018 from the Canadian Parliamentary Budget Office. Taking a mid-point of the range at $5.2 billion, and ignoring all the other cannabis producers currently, we can see that four of the largest publicly traded cannabis producers in Canada currently have market capitalizations that are approximately equal to twice the projected 2018 market size for both recreational and medicinal marijuana in Canada (numbers which I believe to be higher than what reality could show).

Again, the market capitalizations of only four companies already amounts to almost exactly twice the projected sales for 2018.

As I’ve mentioned in a previous article, I have many issues with the report from the Canadian Parliamentary Budget Office; however, the issues with projected market size aside, it is clear to me that cannabis valuations make no sense.

I invite long-term, value-oriented investors to get a spreadsheet out and try to make the numbers work. I dare you. Just try.

Stay Foolish, my friends.

 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. David Gardner owns shares of Amazon. Tom Gardner owns shares of Shopify. The Motley Fool owns shares of Amazon, Shopify, and SHOPIFY INC.

More on Investing

Sliced pumpkin pie
Dividend Stocks

2 Delicious Dividend Stocks I Plan to Add to My TFSA in October

These dreamy dividend stocks can provide you with endless dividends in your TFSA. And it's why I'm considering them right…

Read more »

The letters AI glowing on a circuit board processor.
Tech Stocks

Is Nvidia’s Growth Sustainable?

Nvidia stock soars 1,069% in 2 years. Is this AI chip titan's growth sustainable, or are we witnessing a bubble…

Read more »

Canada day banner background design of flag
Investing

3 Growth Stocks to Buy Now and Hold Forever

These Canadian growth stocks have delivered stellar returns but still have room for growth and can deliver solid capital gains…

Read more »

Hand Protecting Senior Couple
Dividend Stocks

TFSA Pension: How Couples Can Earn $9,500 per Year in Tax-Free Passive Income

This investing strategy can reduce risk and boost returns.

Read more »

calculate and analyze stock
Investing

If You Had Invested $1,000 in Dollarama Stock 5 Years Ago, This Is How Much You’d Have Now

As Dollarama's share price consistently grows year over year, here's how much long-term investors are making owning the top stock.

Read more »

shopper buys items in bulk
Dividend Stocks

9.9% Dividend Yield? I’ll Be Buying This TSX Passive-Income Stock in Bulk

Why make investing complicated? This ETF makes earning monthly income easy.

Read more »

worker holds seedling in soybean field
Investing

Got $10,000? Here’s How It Could Become $100,000

Investing in smart small cap-stocks could be a faster way to multiply your wealth.

Read more »

Canadian dollars in a magnifying glass
Investing

2 High-Yield Dividend ETFs to Buy to Generate Passive Income

These two high-yield Hamilton ETFs pay monthly and offer exposure to real assets.

Read more »